Drug Profile
Danvatirsen - AstraZeneca/Ionis Pharmaceuticals
Alternative Names: AZD-9150-sodium; AZD9150; Danvatirsen-sodium; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3RxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Isis Pharmaceuticals
- Developer Acerta Pharma; AstraZeneca; Flamingo Therapeutics; Ionis Pharmaceuticals; MedImmune; Montefiore Medical Center; National Cancer Institute (USA)
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant ascites; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Phase I/II Liver cancer; Non-Hodgkin's lymphoma
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- No development reported Diffuse large B cell lymphoma
Most Recent Events
- 01 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia (In volunteers, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT05986240)
- 01 Oct 2023 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In volunteers, Monotherapy) in USA (IV) (NCT05986240)
- 01 Oct 2023 Phase-I clinical trials in Myelodysplastic syndromes (In volunteers, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT05986240)